No cases of inflammation observed after 12 months with Phase 3 formulation of pegcetacoplan in patients with advanced geographic atrophy (GA) Decrease in mean lesion
MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Results support, for the first time, the safety and potential efficacy of an
MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Folate receptor alpha most commonly overexpressed on tumour cells in ovarian cancer London,
MOv18 IgE is currently in phase 1 clinical trial in cancer patients with advanced solid tumours Folate receptor alpha most commonly overexpressed on tumour cells